Who is sponsoring NCT01906944?

NCT01906944 is sponsored by Mayo Clinic.

What condition does NCT01906944 study?

NCT01906944 studies Abdominal Pain.

What drugs are being tested in NCT01906944?

Interventions: Bupivacaine 0.25%, Triamcinolone.

What is the status of NCT01906944?

NCT01906944 is currently COMPLETED.

Last reviewed 2020-05-12 · How we verify

Ultrasound Guided Transversus Abdominis Plane Block vs. Trigger Point Injection for Abdominal Wall Pain: A Randomized Comparative Trial

NCT01906944 Phase 2 COMPLETED

Patients with chronic abdominal pain- with a component of abdominal wall pain- are often treated with trigger point injections. This study will help to determine if a block within the transversus abdominis plane (TAP) will provide superior analgesic benefit to a trigger point injection as therapy for these patients.

Details

Lead sponsor	Mayo Clinic
Phase	Phase 2
Status	COMPLETED
Enrolment	62
Start date	2012-01
Completion	2019-08-18

Conditions

Abdominal Pain

Interventions

Bupivacaine 0.25%
Triamcinolone

Primary outcomes

Change in Mean Numerical Pain Score — baseline to 6 months
Pain intensity will be assessed using the 11-point Numerical Pain Score questionnaire where "0" denotes no pain and "10" signifies the most intense pain imaginable.

Countries

United States